Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed CFO
Quarterly results
Acq. announced
Director departure
CC transcript
ACHIEVE LIFE SCIENCES, INC. (ACHV) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "Achieve Life Sciences Reports Financial Results for Second Quarter 2023 and Provides Corporate Update Company to host conference call tomorrow, Tuesday, August 15, 2023, at 8:30 AM EDT SEATTLE, Wash and VANCOUVER, British Columbia, August 14, 2023 — Achieve Life Sciences, Inc. , a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced second quarter 2023 financial results and provided an update on the cytisinicline development program. Recent Highlights • Publication of Phase 3 ORCA-2 trial results in the Journal of the American Medical Association • Reported statistically significant smoking cessation benefit for cytisinicline in the confirmatory Phase 3 ORCA-..."
06/09/2023 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Third Amended and Restated Certificate of Incorporation, filed June 8, 2023"
05/25/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: ". IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY. 31",
"Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering SEATTLE, Wash. and VANCOUVER, British Columbia, May 25, 2023 -- Achieve Life Sciences, Inc. , a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 3,000,000 shares of common stock at a price of $5.50 per share in a registered direct offering. The aggregate gross proceeds from this offering are expected to be approximately $16.5 million, prior to deducting placement agent fees and estimated offering expenses. The Company intends to use the proceeds from the o..."
05/23/2023 8-K Investor presentation
Docs: "References 1 World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017. 2 U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014. 3 Cornelius ME, Loretan CG, Jamal A, et al. Tobacco Product Use Among Adults – United States, 2021. MMWR Morb Mortal Wkly Rep 2023;72:475–483. 4Park Lee E, Ren C, Cooper M, Cornelius M, Jamal A, Cullen KA. Tobacco Product Use Among Middle and High School Students – United States, 2022. Morbidity and Mortality Weekly Report, 2022; 71:45.",
"2 3 4 5 6 7 8 9 10 11 12 16 20 24"
05/17/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "2023 CONTINGENT CONVERTIBLE DEBT AGREEMENT THIS 2023 CONTINGENT CONVERTIBLE DEBT AGREEMENT is dated as of the Effective Date among SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY , in its capacity as administrative agent and collateral agent , SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY, as a lender, SVB Innovation Credit Fund VIII, L.P., a Delaware limited partnership , as a lender, INNOVATION CREDIT FUND VIII-A, L.P., a Delaware limited partnership , as a lender , and and the borrower listed on Schedule I hereto . WHEREAS, each of the Borrower, Innovation and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company , as lender and as agent thereunder, have heretofore entered into that certain 2021 Contingent Convertible Debt...",
"RECITALS WHEREAS, the Company and the Lenders are parties to that certain 2023 Contingent Convertible Debt Agreement of even date herewith, as amended or otherwise modified or supplemented and in effect from time to time ; and WHEREAS, Company and the Lenders desire to provide for certain rights of registration under the Securities Act of 1933, as amended with respect to the Conversion Shares . NOW, THEREFORE, in consideration of the promises, covenants and conditions set forth herein, the parties hereto hereby agree as follows: 1. Registration Rights. 1.1 Definitions. Capitalized terms not otherwise defined herein shall have the meaning ascribed to them in the Loan Agreement. As used in this Agreement, the following terms shall have the meanings set forth below: “Affiliate” ..."
05/09/2023 8-K Quarterly results
Docs: "Consolidated Statements of Loss Three months ended March 31, 2023 2022 Operating expenses: Research and development 5,534 4,388 General and administrative 3,044 2,838 Total operating expenses 8,578 7,226 Loss from operations Other income Net loss $ $ Basic and diluted net loss per share $ $ Weighted average number of basic and diluted common shares 17,917,769 9,458,745 Consolidated Balance Sheets March 31, December 31, 2023 2022 Assets: Cash and cash equivalents $ 16,514 $ 24,771 Prepaid expenses and other current assets 1,710 2,559 Other assets and restricted cash 68 123 Right-of-use assets 109 66 License agreement 1,363 1,418 Goodwill 1,034 1,034 Total assets $ 20,798 $ 29,971 Liabilities and stockholders' equity: Accounts payable and accrued liabilities $ 3,872 $ 5,470 Current portion..."
03/30/2023 8-K Quarterly results
03/23/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment to the Cooperation Agreement, by and among Achieve Life Sciences, Inc., Dialectic Capital Management, LP and the other parties set forth on the signature pages thereto"
03/16/2023 8-K Quarterly results
Docs: "Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update Company to host conference call March 16, 2023, at 4:30 PM EST"
03/06/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Cooperation Agreement, by and among Achieve Life Sciences, Inc., Dialectic Capital Management, LP and the other parties set forth on the signature pages thereto"
11/25/2022 8-K Quarterly results
11/18/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Common Stock Purchase Warrant",
"Form of Subscription Agreement",
"Form of Registration Rights Agreement",
"Achieve Life Sciences Announces Private Placement of $18.9 Million"
11/14/2022 8-K Quarterly results
Docs: "Achieve Reports Financial Results for Third Quarter 2022 and Provides Corporate Update Company to host conference call at 4:30 PM EST today, November 14, 2022"
08/11/2022 8-K Quarterly results
06/01/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/27/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Loan and Security Agreement, among Achieve Life Sciences, Inc. and Silicon Valley Bank",
"First Amendment to 2021 Contingent Convertible Debt Agreement by and among Achieve Life Sciences, Inc., Silicon Valley Bank, and SVB Innovation Credit Fund VIII, L.P",
"Achieve Life Sciences Announces Successful, Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers Clinically robust and statistically significant results in primary and secondary endpoints for both 6- and 12-week cytisinicline treatment compared to placebo",
"Achieve Life Sciences, Inc. Corporate Presentation"
03/10/2022 8-K Quarterly results
12/22/2021 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Contingent Convertible Debt Agreement, among Achieve Life Sciences, Inc., Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P",
"WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY."
11/09/2021 8-K Quarterly results
Docs: "Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development"
08/12/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Achieve Reports Financial Results for Second Quarter 2021 and Provides Corporate Update"
05/25/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
03/11/2021 8-K Quarterly results
11/12/2020 8-K Quarterly results
Docs: "Achieve Reports Financial Results for Third Quarter 2020 and Provides Corporate and Cytisinicline Development Update"
10/22/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "were one- and one-half times more likely to have quit smoking at six months compared to those who received Chantix. Importantly, subjects on cytisinicline experienced significantly fewer side effects, including significantly less nausea"
10/21/2020 8-K Termination of a Material Definitive Agreement
09/30/2020 8-K Quarterly results
08/20/2020 8-K Quarterly results
08/06/2020 8-K Quarterly results
08/04/2020 8-K Quarterly results
07/30/2020 8-K Quarterly results
06/29/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy